Launch planning in an ever-evolving policy and regulatory landscape
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.
Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.
Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics.
Designing a coding gameplan for a soon-to-launch infused biologic
A biopharma company needed an inpatient coding analysis for their new medication.
Lining up support for a New Technology Add-on Payment in a rare-disease treatment
A biopharma company wanted to know the likelihood of receiving an NTAP after launching an inpatient treatment.
Using published evidence and compendia to support expanded coverage for an off-label medication dosage
A pharma company needed to evaluate the likelihood that drug compendia would positively rate an off-label dosage of an FDA-approved medication to support additional payer coverage.
Pricing an oral formulation for a bioequivalent COPD product
A biopharma company needed an appropriate pricing model for a new tablet formulation of a successful existing infusion.